New mRNA Vaccine Reduces Risk of Melanoma Recurrence by Over 40 Percent

A personalized mRNA vaccine reduced the risk of melanoma recurrence by over 40% in a Phase 3 trial, according to results announced this week. The vaccine is tailored to each patient's tumor, marking another milestone in mRNA cancer treatment. Researchers say the findings underscore the technology's promise beyond COVID-19, potentially reshaping adjuvant therapy for high-risk melanoma.